Khondrion BV
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.khondrion.com
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
Phase 3
Not yet recruiting
- Conditions
- Mitochondrial DiseasesMaternally Inherited Diabetes and Deafness (MIDD)Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Khondrion BV
- Target Recruit Count
- 150
- Registration Number
- NCT06451757
The KHENERGYC Study
Phase 2
Suspended
- Conditions
- Mitochondrial DiseasesMitochondrial DNA tRNALeu(UUR) m.3243A<G MutationMELASSubacute Necrotizing Encephalomyelopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Khondrion BV
- Target Recruit Count
- 24
- Registration Number
- NCT04846036
- Locations
- 🇳🇱
Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
The KHENEREXT Study
Phase 2
Completed
- Conditions
- Maternally Inherited Diabetes and Deafness (MIDD)Mitochondrial DiseasesMitochondrial DNA tRNALeu(UUR) m.3243A<G MutationChronic Progressive External Ophthalmoplegia (CPEO)Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS)
- Interventions
- Drug: Oral administration of 100 mg KH176 twice daily
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Khondrion BV
- Target Recruit Count
- 11
- Registration Number
- NCT04604548
- Locations
- 🇩🇰
Rigshospitalet, University of Copenhagen, Kopenhagen, Denmark
🇩🇪Klinikum der Universität München Friedrich-Baur-Institut, München, Germany
🇳🇱Radboud University Medical Center, Nijmegen, Netherlands
The KHENERGYZE Study
Phase 2
Completed
- Conditions
- Mitochondrial MyopathiesMitochondrial EncephalomyopathiesMitochondrial DiseasesMELAS SyndromeMIDD
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Khondrion BV
- Target Recruit Count
- 27
- Registration Number
- NCT04165239
- Locations
- 🇩🇰
Rigshospitalet, University of Copenhagen, Kopenhagen, Denmark
🇩🇪Friedrich-Baur Institut, München, Bayern, Germany
🇳🇱Radboud University Medical Center, Nijmegen, Netherlands
The KHENERGY Study
Phase 2
Completed
- Conditions
- Mitochondrial EncephalomyopathiesMIDDMitochondrial MyopathiesMitochondrial DiseasesMELAS
- Interventions
- Drug: placebo
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Khondrion BV
- Target Recruit Count
- 20
- Registration Number
- NCT02909400
- Locations
- 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands
A Dose-escalating Clinical Trial With KH176
Phase 1
Completed
- Conditions
- LHONMELASLeigh SyndromeMitochondrial DiseaseMitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
- Interventions
- Drug: placebo
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Khondrion BV
- Target Recruit Count
- 32
- Registration Number
- NCT02544217
- Locations
- 🇧🇪
Drug Research Unit Ghent, Ghent, Belgium